泛艾霉素
![]() | |
![]() | |
Ellence | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603003 |
| |
给药 | |
ATC碼 | |
| |
NA | |
77% | |
药物 | |
经 | |
识别 | |
| |
CAS | 56420-45-2 ![]() |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
C27H29NO11 | |
543.53 g·mol−1 | |
3D | |
| |
|
泛艾霉素(INN
历史
[编辑]1980
泛艾霉素
参 见
[编辑]参考 文献
[编辑]- ^ Wierstra, Inken. FOXM1 (Forkhead box M1) in Tumorigenesis 119: 191–419. 2013. ISSN 0065-230X. doi:10.1016/B978-0-12-407190-2.00016-2.
- ^ Kwok, Karl K.; Vincent, Erica C.; Gibson, James N. Antineoplastic Drugs: 530–562. 2017. doi:10.1016/B978-0-323-39307-2.00036-9.
- ^ Bonfante V, Bonadonna G, Villani F, Martini A. Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer. Recent Results in Cancer Research. 1980, 74: 192–9. ISBN 978-3-642-81490-7. PMID 6934564. doi:10.1007/978-3-642-81488-4_24.
- ^ Oncology Approval: epirubicin hydrochloride (Ellence). On Target. Target Health Inc. September 15, 1999 [2007-08-04]. (
原始 内容 存 档于2008-05-10).
|